Oncology | Home | MIMS Malaysia

Malaysia
Search
Sign In

Oncology

Oncology

Home News Diseases Conferences Special Reports Multimedia

Liquid biopsy a promising tool for establishing diagnosis in GBM patients

Dr. Joseph Delano Fule Robles, 2 days ago

Liquid biopsy is demonstrated to be a quick, inexpensive diagnostic modality that can be performed multiple times to help establish a diagnosis of glioblastoma multiforme (GBM) without high-risk neurosurgical interventions.

Eribulin on par with dacarbazine in patients with leiomyosarcoma

Stephen Padilla, 3 days ago

Eribulin is as effective as dacarbazine in patients with leiomyosarcoma (LMS), with both agents showing manageable safety profiles, results of a subgroup analysis from a phase III, open-label, randomized study have shown.

Denosumab favourably affects bone health, HR+ breast cancer outcomes

Jairia Dela Cruz, 4 days ago

Postmenopausal women with hormone receptor (HR)-positive breast cancer fare well with the addition of denosumab to aromatase inhibitors, with data from the phase III ABCSG-18 trial showing that the antiresorptive drug cuts the risk of fractures and confers a modest but significant improvement in disease-free survival with a favourable tolerability profile.

No-chemo regimen in HER2+ metastatic breast cancer shortens PFS with no OS impact

Roshini Claire Anthony, 6 days ago

Omitting first-line chemotherapy for patients with metastatic HER2+ breast cancer treated with pertuzumab plus trastuzumab did not affect overall survival (OS) despite shorter progression-free survival (PFS), according to updated results of the phase II PERNETTA* trial.

Disparity seen between anticoagulation prescription, guidelines

6 days ago

Prescribing of prophylactic anticoagulation appears to be inconsistent with current practice guidelines, suggests a recent study. However, there appears to be lower thromboembolic events than recorded in previously published literature.

Excerpts from the MY-COMPASSION Expert Meeting

30 Jan 2019

In March 2018, sublingual fentanyl citrate (SLF; Abstral®, Menarini) was made available in Malaysia. SLF is a rapid-onset opioid (ROO) indicated for the management of breakthrough cancer pain (BTcP) episodes in patients that are opioid-tolerant. In July 2018, Menarini organized an expert meeting, aptly named Malaysian Collaborative Meeting of Pain Specialists to Improve Oncology Management (MY-COMPASSION), comprising of key figures in anaesthesiology, palliative care and oncology to discuss current insights into local BTcP management. Below are highlights from the meeting.

Comprehensive genomic profiling in oncology – from vision to reality

Dr. Jeffrey Ross, Dr. Rohit Lal, Prof. Alwin Krämer, Dr. Rebecca Dent, Prof. Rafal Dziadziuszko, 24 Jan 2019

Comprehensive genomic profiling (CGP) has emerged as a key driving force behind personalized cancer care. With the wealth of data available with CGP, medical oncologists now have in their armamentarium a tool that could enable them to provide patients with the optimum treatment. At a Roche Foundation Medicine-sponsored symposium held at the 2018 European Society of Medical Oncology (ESMO) Congress in Munich, Germany, a panel of experts reviewed key data on CGP, with a focus on the treatment of advanced cancers.

Targeted Immunotherapy against PD-L1 in NSCLC

21 Nov 2018

Recently, a Roche-sponsored dinner symposium was held in conjunction with the launch of atezolizumab (Tecentriq®, Roche) at Royale Chulan, Kuala Lumpur. Important insights into the evolving treatment landscape of anticancer treatment, and the increasingly prominent role of immunotherapy were gathered from a distinguished panel, including Dato’ Dr Mohamed Ibrahim, Professor Dr Rolf A. Stahel, Dr Voon Pei Jye, and Associate Professor Dr Tho Lye Mun. Here are the highlights of the meeting.

A report of the first patient in Malaysia who had successfully completed 16 cycles of brentuximab vedotin

19 Sep 2018

In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.^1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.⁴ Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.⁵

Rapid onset opioids for the optimized treatment of breakthrough cancer pain

24 Jul 2018

At a recent dinner symposium held during the Abstral® Grand Launch at Le Meridien Putrajaya, Dr Michael Überall spoke on the management of breakthrough cancer pain (BTcP) and highlighted the role of sublingual fentanyl ([SLF], Abstral®; A. Menarini Pte Ltd) in the optimization of BTcP in cancer patients.

Treatment-free remission: Who, how and why?

21 May 2018

At the recent American Society of Haematology Annual Meeting 2017, Professor François-Xavier Mahon reviewed recent studies related to tyrosine kinase inhibitor (TKI) cessation in patients with chronic myeloid leukaemia (CML) who have achieved sustained deep molecular response (DMR).

Pooled data support efficacy of entrectinib for ROS1+ NSCLC

Elvira Manzano, 12 May 2019

Treatment with the ROS1 inhibitor entrectinib yielded deep and durable responses in patients with ROS1 fusion-positive non–small cell lung cancer (ROS1+ NSCLC), including in those with brain metastases, according to a pooled analysis of three studies.

Savolitinib plus osimertinib combination therapy triumphs in treatment of mutated lung cancer

Dr. Joseph Delano Fule Robles, 07 May 2019

Combination therapy with the MET inhibitor savolitinib and the EGFR inhibitor osimertinib showed robust and durable clinical responses among patients with EGFR-mutated and MET-amplified non-small-cell lung cancer (NSCLC), according to results of the phase Ib TATTON study presented at AACR 2019.

Is immunotherapy suitable for elderly patients with advanced NSCLC?

Roshini Claire Anthony, 06 May 2019

Two studies presented at ELCC 2019 provided contrasting outcomes on the efficacy of immunotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC).

Gilteritinib improves survival in relapsed or refractory AML

Dr. Joseph Delano Fule Robles, 06 May 2019

Gilteritinib, a novel inhibitor of the tyrosine kinase FLT3, improves survival outcomes among patients with relapsed or refractory acute myeloid leukaemia (AML) with FLT3 mutations vs standard chemotherapy, according to results of the phase III ADMIRAL trial reported at the American Association for Cancer Research (AACR) Annual Meeting 2019 held in Atlanta, Georgia, US.

Rucaparib shows encouraging responses in advanced pancreatic cancer

Elaine Soliven, 06 May 2019

Oral rucaparib as maintenance treatment showed encouraging clinical responses in patients with advanced BRCA1-, BRCA2-, or PALB2-mutated pancreatic cancer, according to an interim analysis presented at AACR 2019.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!